Science
13,824 nonnatural genes designed to bypass evolutionary constraints Superior performance demonstrated compared with natural transcription factors

A platform has been developed to boost the antitumor function of CAR T cells by designing synthetic transcription factors at scale. The researchers created nonnatural genes that bypass the constraints of natural evolution and found that they outperformed existing transcription factors.
Oliver Takacsi-Nagy and colleagues announced the findings on the 27th, saying they had published the study in the international journal Cell.
The researchers developed DESynR, a high-throughput combinatorial assembly method that combines structural domain fragments from natural genes to create thousands of new genes tagged with barcodes. Using the method, they designed 13,824 DESynR AP-1 transcription factors.
DESynR AP-1 transcription factors significantly outperformed natural transcription factors across several in vitro and in vivo functions in human CAR T cells. Notably, some domains used in the top-performing DESynR transcription factors came from natural transcription factors expressed at extremely low levels in T cells.
These synthetic transcription factors optimized key gene expression programs in T cells. Specifically, they regulated genes associated with exhaustion, effector function, cytotoxicity, stemness and persistence; some also borrowed programs from non-T-cell types.
In particular, CAR T cells expressing the JUN-FOS-BATF combination showed substantially enhanced function in several in vitro and in vivo models. They also outperformed cells overexpressing natural transcription factors. At the transcriptional level, the combination reduced expression of exhaustion-related genes and increased expression of genes associated with cytotoxicity and stemness.
Mechanistically, the cis-regulatory elements bound by DESynR transcription factors did not differ substantially from those bound by natural AP-1 transcription factors. Most bound commonly to T-cell-specific genes. The researchers hypothesized that their induction of different gene expression patterns was due to regulation of AP-1 dimerization.
The researchers found that classical JUN:FOS AP-1 dimers enhanced cytotoxicity and that FOS availability may be limited under normal conditions. By contrast, BATF expression was found to reduce cytotoxicity.
The method also showed potential for application to the ETS and FOX transcription factor families. The researchers said it could be extended to other protein families, combinations of multiple families, or combinations with synthetic domains.
The researchers noted, however, that the entire DESynR library was selected based on improvement in a single function: proliferation and persistence. Assessments of other functions, such as cytotoxicity and stemness, were limited by this simplified process.
"We designed nonevolutionary functional genes from existing domain components to bypass evolutionary constraints and selected them directly in clinically relevant primary human cell models," the researchers said. "This provides a powerful framework to accelerate the elucidation of basic biology and the development of next-generation cell therapies."

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Blocking Disease Proteins With ‘Molecular Gates’ … Gate Bioscience Prepares to Enter the Clinic

Rezolute Meets Phase 3 Goal in Tumor Hyperinsulinism, Shares Rise Ahead of FDA Meeting

Regeneron’s POTS drug succeeds in Phase 2; Phase 3 to begin in first half of next year

Egene Receives Approval to Amend Phase 2/3 Trial of Quadrivalent Meningococcal Vaccine

GC Biopharma Develops Korea’s First Generative AI Drug Safety Monitoring Software, Focused on Preventing Missed Cases

Daewoong Pharmaceutical Wins Phase 1 Approval for Drug to Regenerate Intestinal Mucosa: “Beyond Immunosuppression”